USA flag logo/image

An Official Website of the United States Government

Identifying drug toxicity signatures using QCarrays

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
70523
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
CA106153
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
PHYSIOGENIX, INC.
PHYSIOGENIX, INC. 10437 INNOVATION DR, STE 325 WAUWATOSA, WI 53226-4838
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: Identifying drug toxicity signatures using QCarrays
Agency: HHS
Contract: 1R43CA106153-01A1
Award Amount: $498,610.00
 

Abstract:

DESCRIPTION (provided by applicant): This Phase I SBIR project uses a new Quality Control microarray (QCarray) technology to generate Drug Toxicity Signatures (DTSs) for predicting liver toxicity in rat. The QCarray enables each element on every array to have a quality control (QC) score and markedly reduces a common source of error: fabrication of the cDNA microarrays. A second source of variability in arrays is genetic heterogeneity; therefore, we will benchmark the QCarray and look for DTSs using the PharmGenix Panel. The PharmGenix Panel models a heterozygous, variable genetic background in a controlled setting while reliably detecting drug toxicity. PhysioGenix will leverage archived tissues from previous PharmGenix drug studies and generate liver-specific DTSs to four different hepatotoxins. Matarray software will QC and normalize array data while principal component analysis will cluster expression patterns according to clinical chemistry, to help to determine informative DTSs. Phase II efforts will generate DTSs for toxicity to kidney and heart, and compare the liver DTSs to non-human primates. The common DTSs will be posited to be predictive biomarkers in the drug development process. Deliverables from this project will be of interest to the FDA and marketed to pharmaceutical companies for implementation into their existing drug development process.

Principal Investigator:

Steven H. Nye
4144316600
SNYE@PHYSIOGENIX.COM

Business Contact:


4143057465
Small Business Information at Submission:

PHYSIOGENIX, INC.
PHYSIOGENIX, INC. 10437 INNOVATION DR, STE 325 WAUWATOSA, WI 53226

EIN/Tax ID: 391906674
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No